Corvus Pharmaceuticals (NASDAQ:CRVS) Earns Buy Rating from Mizuho

Share on StockTwits

Mizuho reiterated their buy rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a research report sent to investors on Thursday morning, AnalystRatings.com reports. Mizuho currently has a $7.00 target price on the stock.

CRVS has been the topic of several other research reports. Zacks Investment Research downgraded Corvus Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, July 13th. ValuEngine upgraded Corvus Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, April 2nd. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Corvus Pharmaceuticals has an average rating of Buy and a consensus price target of $7.25.

NASDAQ:CRVS opened at $4.24 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.96 and a current ratio of 5.96. Corvus Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $6.88. The company has a fifty day moving average of $3.60 and a two-hundred day moving average of $3.54.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, July 30th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). As a group, sell-side analysts anticipate that Corvus Pharmaceuticals will post -1.19 earnings per share for the current year.

In related news, major shareholder Holdings A/S Novo sold 1,538,062 shares of the stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $5.31, for a total value of $8,167,109.22. Following the completion of the sale, the insider now owns 2,130,938 shares of the company’s stock, valued at $11,315,280.78. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 45.12% of the stock is owned by corporate insiders.

Several hedge funds have recently made changes to their positions in CRVS. Squarepoint Ops LLC purchased a new stake in shares of Corvus Pharmaceuticals in the first quarter valued at about $52,000. Two Sigma Advisers LP grew its stake in shares of Corvus Pharmaceuticals by 74.2% in the 1st quarter. Two Sigma Advisers LP now owns 28,880 shares of the company’s stock valued at $61,000 after buying an additional 12,300 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Corvus Pharmaceuticals during the 1st quarter worth approximately $63,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Corvus Pharmaceuticals by 4.7% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 85,604 shares of the company’s stock valued at $181,000 after buying an additional 3,804 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Corvus Pharmaceuticals by 79.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 107,176 shares of the company’s stock valued at $583,000 after acquiring an additional 47,293 shares during the last quarter. 73.89% of the stock is currently owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Read More: Index Funds

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 

Latest News

Different Types of Research Papers
Different Types of Research Papers
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing


 
© 2006-2020 BBNS.